PL3411036T3 - 3,5-dipodstawione pirazole przydatne jako inhibitory kinazy punktu kontrolnego 1 (chk1) oraz ich preparaty i zastosowanie - Google Patents
3,5-dipodstawione pirazole przydatne jako inhibitory kinazy punktu kontrolnego 1 (chk1) oraz ich preparaty i zastosowanieInfo
- Publication number
- PL3411036T3 PL3411036T3 PL16888753T PL16888753T PL3411036T3 PL 3411036 T3 PL3411036 T3 PL 3411036T3 PL 16888753 T PL16888753 T PL 16888753T PL 16888753 T PL16888753 T PL 16888753T PL 3411036 T3 PL3411036 T3 PL 3411036T3
- Authority
- PL
- Poland
- Prior art keywords
- chk1
- preparations
- inhibitors
- applications
- checkpoint kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16888753.7A EP3411036B1 (en) | 2016-02-04 | 2016-02-04 | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
| PCT/CN2016/073454 WO2017132928A1 (en) | 2016-02-04 | 2016-02-04 | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3411036T3 true PL3411036T3 (pl) | 2022-04-04 |
Family
ID=59500387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16888753T PL3411036T3 (pl) | 2016-02-04 | 2016-02-04 | 3,5-dipodstawione pirazole przydatne jako inhibitory kinazy punktu kontrolnego 1 (chk1) oraz ich preparaty i zastosowanie |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11116767B2 (pl) |
| EP (1) | EP3411036B1 (pl) |
| JP (1) | JP6794609B2 (pl) |
| KR (1) | KR102159442B1 (pl) |
| CN (1) | CN108601781B (pl) |
| AU (1) | AU2016391377B2 (pl) |
| CA (1) | CA3013514C (pl) |
| DK (1) | DK3411036T3 (pl) |
| ES (1) | ES2906785T3 (pl) |
| HR (1) | HRP20220351T1 (pl) |
| HU (1) | HUE057976T2 (pl) |
| PL (1) | PL3411036T3 (pl) |
| PT (1) | PT3411036T (pl) |
| SI (1) | SI3411036T1 (pl) |
| TW (1) | TWI623533B (pl) |
| WO (1) | WO2017132928A1 (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3464275B1 (en) | 2016-05-26 | 2024-05-08 | Recurium IP Holdings, LLC | Egfr inhibitor compounds |
| CN112457306A (zh) * | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| US11634424B2 (en) | 2019-11-29 | 2023-04-25 | Medshine Discovery Inc. | Diazaindole derivative and use thereof as CHK1 inhibitor |
| TWI810426B (zh) * | 2020-01-10 | 2023-08-01 | 長庚大學 | 醫藥組合物於製備治療癌症藥物之用途與評估方法 |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| AU2021389190A1 (en) | 2020-11-30 | 2023-06-29 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1h-pyrazol-3-amine derivative |
| KR20240021188A (ko) * | 2021-05-27 | 2024-02-16 | 바운드리스 바이오, 인크. | 체크포인트 키나제 1(chk1) 억제제 및 그의 용도 |
| GB202107924D0 (en) * | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
| MX2024007910A (es) | 2021-12-24 | 2024-09-04 | Sumitomo Pharma Co Ltd | Derivado de 1h-pirazol-3-amina que tiene una estructura principal bicíclica. |
| IT202200000920A1 (it) | 2022-01-20 | 2023-07-20 | Fondazione St Italiano Tecnologia | "Derivati del 4-cromone come inibitori della polimerasi RdRp del virus SARS-CoV-2 e metodo per la loro preparazione” |
| GB202201825D0 (en) | 2022-02-11 | 2022-03-30 | Genome Res Ltd | Methods of treatment |
| IT202200007988A1 (it) | 2022-04-22 | 2023-10-22 | Fondazione St Italiano Tecnologia | Derivati del 4-cromone come inibitori della polimerasi ¿ come agenti antitumorali e metodo per la loro preparazione |
| JP7546104B2 (ja) * | 2022-05-27 | 2024-09-05 | 住友ファーマ株式会社 | ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体からなる医薬 |
| EP4534100A1 (en) * | 2022-05-27 | 2025-04-09 | Sumitomo Pharma Co., Ltd. | Therapeutic for cancer refractory to immune checkpoint inhibitor |
| GB202213792D0 (en) | 2022-09-21 | 2022-11-02 | Benevolentai Bio Ltd | New compounds and method |
| CN116199569A (zh) * | 2023-02-22 | 2023-06-02 | 浙江科聚生物医药有限公司 | 一种抗肿瘤药物林扎戈利关键酚类中间体的制备方法 |
| WO2025027560A1 (en) | 2023-08-01 | 2025-02-06 | Fondazione Istituto Italiano Di Tecnologia | New rhoj/cdc42 inhibitors developed for the treatment of cancer, benign tumors, retinal disorders, vascular disorders, and cardiomyopathies |
| WO2025101691A1 (en) | 2023-11-08 | 2025-05-15 | Exelixis, Inc. | Methods for treating cancer using compounds that inhibit pkmyt1 |
| WO2025109026A1 (en) | 2023-11-21 | 2025-05-30 | Intervet International B.V. | Process for the preparation of 4-fluoro-3-methoxyaniline |
| GB202403910D0 (en) | 2024-03-19 | 2024-05-01 | Benovental Cambridge Ltd | New processes and intermediates for pharmaceutical products |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| BRPI0412820A (pt) * | 2003-07-25 | 2006-09-26 | Pfizer | compostos de aminopirazol e utilização como inibidores de chk1 |
| US20050148643A1 (en) | 2003-08-19 | 2005-07-07 | Agouron Pharmaceuticals, Inc. | Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme |
| DE602004031777D1 (en) | 2004-01-05 | 2011-04-21 | Astrazeneca Ab | Thiophenderivate als chk-1-inhibitoren |
| KR20070043996A (ko) | 2004-07-02 | 2007-04-26 | 이코스 코포레이션 | Ｃｈｋ1의 억제에 유용한 화합물 |
| CA2577880A1 (en) | 2004-08-19 | 2006-02-23 | Icos Corporation | Compounds useful for inhibiting chk1 |
| KR20090031459A (ko) | 2005-03-29 | 2009-03-25 | 이코스 코포레이션 | Ｃｈｋ1 억제에 유용한 헤테로아릴 우레아 유도체 |
| PA8850801A1 (es) | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| US8314108B2 (en) | 2008-12-17 | 2012-11-20 | Eli Lilly And Company | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts |
| JO3145B1 (ar) | 2010-11-08 | 2017-09-20 | Lilly Co Eli | مركبات مفيدة لتثبيط chk1 |
| RU2017127088A (ru) * | 2010-11-16 | 2019-02-04 | Эррэй Биофарма Инк. | Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1 |
| GB201402277D0 (en) * | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
-
2016
- 2016-02-04 WO PCT/CN2016/073454 patent/WO2017132928A1/en not_active Ceased
- 2016-02-04 US US16/074,195 patent/US11116767B2/en active Active
- 2016-02-04 CN CN201680066535.6A patent/CN108601781B/zh active Active
- 2016-02-04 CA CA3013514A patent/CA3013514C/en active Active
- 2016-02-04 ES ES16888753T patent/ES2906785T3/es active Active
- 2016-02-04 PL PL16888753T patent/PL3411036T3/pl unknown
- 2016-02-04 HU HUE16888753A patent/HUE057976T2/hu unknown
- 2016-02-04 HR HRP20220351TT patent/HRP20220351T1/hr unknown
- 2016-02-04 AU AU2016391377A patent/AU2016391377B2/en active Active
- 2016-02-04 DK DK16888753.7T patent/DK3411036T3/da active
- 2016-02-04 SI SI201631439T patent/SI3411036T1/sl unknown
- 2016-02-04 PT PT168887537T patent/PT3411036T/pt unknown
- 2016-02-04 KR KR1020187024712A patent/KR102159442B1/ko active Active
- 2016-02-04 JP JP2018541333A patent/JP6794609B2/ja active Active
- 2016-02-04 EP EP16888753.7A patent/EP3411036B1/en active Active
-
2017
- 2017-01-09 TW TW106100635A patent/TWI623533B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016391377A1 (en) | 2018-08-16 |
| JP6794609B2 (ja) | 2020-12-02 |
| KR102159442B1 (ko) | 2020-09-24 |
| JP2019509990A (ja) | 2019-04-11 |
| EP3411036B1 (en) | 2021-12-29 |
| WO2017132928A1 (en) | 2017-08-10 |
| CA3013514A1 (en) | 2017-08-10 |
| KR20180105700A (ko) | 2018-09-28 |
| US20210137918A1 (en) | 2021-05-13 |
| TWI623533B (zh) | 2018-05-11 |
| AU2016391377B2 (en) | 2019-07-18 |
| PT3411036T (pt) | 2022-02-21 |
| HRP20220351T1 (hr) | 2022-05-13 |
| CA3013514C (en) | 2021-11-23 |
| HK1257988A1 (zh) | 2019-11-01 |
| TW201728579A (zh) | 2017-08-16 |
| DK3411036T3 (da) | 2022-01-17 |
| ES2906785T3 (es) | 2022-04-20 |
| CN108601781A (zh) | 2018-09-28 |
| EP3411036A1 (en) | 2018-12-12 |
| US11116767B2 (en) | 2021-09-14 |
| HUE057976T2 (hu) | 2022-06-28 |
| EP3411036A4 (en) | 2019-06-26 |
| SI3411036T1 (sl) | 2022-03-31 |
| CN108601781B (zh) | 2019-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3411036T1 (sl) | 3,5-disubstituirani pirazoli, uporabni kot kontrolne točke inhibitorjev kinaze 1 (CHK1), ter njihovi pripravki in uporaba | |
| ZA201800671B (en) | Pyrazole pyrimidine derivative and uses thereof | |
| ZA201707423B (en) | Imidazolonyl quinolines and use thereof as atm kinase inhibitors | |
| SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
| DK3359541T3 (da) | N-sulfonylerede pyrazol[3,4-b]pyridin-6-carboxamider og fremgangsmåde til anvendelse | |
| DK3297637T3 (da) | Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf | |
| IL247426B (en) | Pyrazole amide derivatives, preparations containing them and their uses | |
| DK3408326T3 (da) | Elastomerartikler, sammensætninger og fremgangsmåder til fremstilling deraf | |
| SG11202103142TA (en) | Heterocyclic kinase inhibitors and uses thereof | |
| IL272055A (en) | 8,1-naphthyridinone compounds and their uses | |
| EP3256450A4 (en) | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof | |
| IL304547A (en) | 3-substituted benzamide derivatives as kinase inhibitors | |
| PT3577094T (pt) | Mistura contendo 3,4-dimetilpirazol e a sua utilização | |
| ZA202004311B (en) | Pyrazole amide compound and application thereof, and fungicide | |
| DK3719021T3 (da) | Inhibitorer af adapterassocieret kinase 1, sammensætninger omfattende disse og fremgangsmåder til anvendelse deraf | |
| IL254152A0 (en) | Pyrimidine derivatives as kinase inhibitors and their medicinal uses | |
| EP3327021A4 (en) | Janus kinase 1 selective inhibitor and pharmaceutical use thereof | |
| EP3476848A4 (en) | BENZOFURANE-PYRAZOLE-AMINE PROTEIN KINASE INHIBITOR | |
| SG11201705088VA (en) | 3,5-diaminopyrazole kinase inhibitors | |
| ZA201908372B (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| IL257735B (en) | 4-(3,3,3-trifluoropropanoyl)octahydro-h1-6,2-methanopyrrolo[3,2-b]pyridin-3-yl pivalates and their synthesis | |
| HK40026701A (en) | Kinase inhibitors and uses thereof | |
| HK40036603A (en) | Heterocyclic compounds and uses thereof | |
| EP3634406C0 (en) | 3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF |